Indeed, the presence of PD-L1 expression may indicate a trend of enhanced antitumor activity favoring PD-1/PD-L1 inhibitors, however, several factors such as the use of distinct assay, different screening thresholds and measure expression on different cells within the tumor microenvironment could bias the findings [50]. The gene discussed is PDCD1; the disease is neoplasm.